| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/10/2001 | WO2001032139A2 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032125A2 Apparatus and process for preparing crystalline particles |
| 05/10/2001 | WO2001032115A1 Transdermal administration of huperzine |
| 05/10/2001 | WO2001032036A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | WO2001032031A2 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | WO2001032029A2 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 05/10/2001 | WO2001021804B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/10/2001 | WO2001019378A3 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
| 05/10/2001 | WO2001012175A8 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/10/2001 | WO2001008505A3 Methods for suppressing appetite and enhancing exercise and recovery |
| 05/10/2001 | WO2001003671A3 Method for producing powdery particle-reduced formulations with the aid of compressed gases |
| 05/10/2001 | WO2000067800A3 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
| 05/10/2001 | WO2000061170A3 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid) |
| 05/10/2001 | WO2000016745A3 Micronised pharmaceutical compositions |
| 05/10/2001 | WO1999052503A3 Rna cancer vaccine and methods for its use |
| 05/10/2001 | US20010001106 Preparing D-mannitol having a specific surface area of not less than about 1 m2/g which comprises treating delta form D-mannitol crystals with a water-soluble solvent followed by drying |
| 05/10/2001 | DE19951795A1 Verwendung von Parvoviren zur Verbesserung des Allgemeinzustandes bei Tumorpatienten oder Patienten mit chronischen oder konsumierenden Erkrankungen Use of parvoviruses to improve the general condition in cancer patients or patients with chronic or consumptive diseases |
| 05/10/2001 | CA2390077A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389973A1 Method of treating amyloid beta precursor disorders |
| 05/10/2001 | CA2389931A1 Antidiabetic formulation and method |
| 05/10/2001 | CA2389917A1 A polymer micelle as monolayer or layer-laminated surface |
| 05/10/2001 | CA2389908A1 Novel apparatus and process for preparing crystalline particles |
| 05/10/2001 | CA2389865A1 Transdermal administration of huperzine |
| 05/10/2001 | CA2389778A1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 05/10/2001 | CA2389704A1 Compositions comprising edible oils and phytosterols and/or phytostanols substantially dissolved therein, method of making the same, and use thereof in treating or preventing cardiovascular disease, and its underlying conditions |
| 05/10/2001 | CA2389690A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | CA2389686A1 Adjuvanted genetic vaccines |
| 05/10/2001 | CA2389680A1 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | CA2389626A1 Method of forming micropores in skin |
| 05/10/2001 | CA2389616A1 Liver selective therapy |
| 05/10/2001 | CA2389605A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | CA2389304A1 Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389236A1 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/10/2001 | CA2389147A1 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 05/10/2001 | CA2388657A1 New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist |
| 05/10/2001 | CA2388354A1 Lactobacillus helvetius producing antihypertensive di- and tripeptides |
| 05/10/2001 | CA2388339A1 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | CA2388159A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | CA2386822A1 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 05/10/2001 | CA2358921A1 Oxetanone derivatives |
| 05/09/2001 | EP1097968A1 Mixtures of silicone elastomers |
| 05/09/2001 | EP1097722A1 Excipient |
| 05/09/2001 | EP1097721A2 Oil-based adjuvant vaccine |
| 05/09/2001 | EP1097715A1 Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient |
| 05/09/2001 | EP1097712A1 Steroid-containing cataplasms and process for producing the same |
| 05/09/2001 | EP1097705A2 Process for the manufacture of a pulverous preparation |
| 05/09/2001 | EP1097696A1 Composition containing waxes and an hydrophilic active unstable in an oxidizing medium and cosmetic use thereof |
| 05/09/2001 | EP1097693A2 Microcapsule system for the environmental induced release of agents |
| 05/09/2001 | EP1097270A1 Use of pit emulsions |
| 05/09/2001 | EP1097165A1 Novel inhibitors of angiogenesis and tumor growth |
| 05/09/2001 | EP1096975A2 Methods for reducing intraocular pressure using a3-adenosine antagonists |
| 05/09/2001 | EP1096962A1 Method of obscuring immune recognition |
| 05/09/2001 | EP1096957A1 Methods and reagents for intramuscular delivery of nucleic acids |
| 05/09/2001 | EP1096944A1 Extracts of zanthoxylum bungeanum, pharmaceutical and cosmetic formulations containing them |
| 05/09/2001 | EP1096940A1 Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus |
| 05/09/2001 | EP1096937A2 Sustained release ranolazine formulations |
| 05/09/2001 | EP1096934A1 Oxazolidinones to treat eye infections |
| 05/09/2001 | EP1096923A1 Blister containing a transdermal therapeutic system and a single dose form of administration |
| 05/09/2001 | EP1096922A1 Improved stable topical ascorbic acid compositions |
| 05/09/2001 | EP1096921A1 Liposomal encapsulated nucleic acid-complexes |
| 05/09/2001 | EP1096919A1 Systems and methods for local delivery of an agent |
| 05/09/2001 | EP1033131A4 Composition of ingredients for a beverage having a delayed aversion effect |
| 05/09/2001 | EP0814824B1 Effervescent composition with dry extract of ginkgo biloba |
| 05/09/2001 | EP0776206B1 Pharmaceutical formulation containing amoxycillin and potassium clavulanate |
| 05/09/2001 | EP0680341B1 Phase shift colloids as ultrasound contrast agents |
| 05/09/2001 | CN1294625A Novel polymerizable fatty acids, phospholipids and poly merized liposomes therefrom |
| 05/09/2001 | CN1294522A Appts. and processes for whole-body hyperthermia |
| 05/09/2001 | CN1294519A Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients |
| 05/09/2001 | CN1294518A Remidies for hepatitis |
| 05/09/2001 | CN1294512A Paroxetine compsns. |
| 05/09/2001 | CN1294511A Medicinal compsns. |
| 05/09/2001 | CN1294510A Multiple-unit sustained release tablets |
| 05/09/2001 | CN1294509A Enteric coated pharmaceutical compsn. and method of mfg. |
| 05/09/2001 | CN1294133A Process for extracting cordycepin and its preparation |
| 05/09/2001 | CN1294017A Ceramide lipsome emulsion containing VA and its preparing process and usage |
| 05/09/2001 | CN1294016A Injection for giving up addiction |
| 05/09/2001 | CN1294012A Aphtha ointment and its preparing process |
| 05/09/2001 | CN1293996A Capsule or microcapsule of superfine notoginseng powder |
| 05/09/2001 | CN1293992A Medicine 'Buyuan Jianmei Wan' |
| 05/09/2001 | CN1293953A 'Xianketie' medicine for treating tinea |
| 05/09/2001 | CN1293952A Chitosan and fibroin mixed microsphere and its usage and preparing process |
| 05/09/2001 | CN1065439C Method for preparing sustained release compsns. |
| 05/09/2001 | CN1065433C Oily prepn. and method of prodn. thereof |
| 05/09/2001 | CN1065428C Matrix type patch preparations |
| 05/09/2001 | CN1065424C Methods and appts. for creating gelatin coating of products |
| 05/09/2001 | CN1065415C Application of protein and lipid composite for modifying taste |
| 05/09/2001 | CA2313711A1 Nonwoven material comprising an adhesive and apertures |
| 05/08/2001 | US6229038 Phosphonate compound containing hydroxylinkage and two carboxy groups that improve water solubility and enhance foaming, detergency, chelation; non-irritable to skin and eyes |
| 05/08/2001 | US6229009 Polycarboxylic based cross-linked copolymers |
| 05/08/2001 | US6228969 Biodegradable polyester urethanes, method for the production and use thereof |
| 05/08/2001 | US6228904 Nanostructured fillers and carriers |
| 05/08/2001 | US6228894 Softgel-compatible composition containing retinol |
| 05/08/2001 | US6228864 Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
| 05/08/2001 | US6228855 Topoisomerase inhibitors; antitumor agents |
| 05/08/2001 | US6228836 Administering cyclic nonapeptide n-terminated with b,b-(3-thiapentamethylene)-b-mercaptopropionic acid |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228605 Detection of helicobacter pylori in the stomach |